Class / Patent application number | Description | Number of patent applications / Date published |
436087000 | Glycoproteins (e.g., hormone, etc.) | 27 |
20080299666 | Novel Peptide-Based Borono-Lectin (PBL) Sensors - Peptide-based borono-lectin sensors, along with their synthesis and analysis and methods of use, are generally described. These sensors use peptides as a scaffold and introduce boronic acid moieties onto the peptide scaffold as the binding site for the targeted analyte (e.g., carbohydrates, glycans, etc.). The boronic acid moieties can be arranged on the protein scaffold in such a manner that a particularly targeted carbohydrate or glycoprotein will bond to the protein scaffold via the boronic acid functionality. Such bonding can indicated the presence or absence of that targeted analyte in the sample. | 12-04-2008 |
20090004750 | Method of Diagnosing Cerebral Infarction - A method of diagnosing cerebral infarction comprising the step of measuring the concentration of nick β2 glycoprotein I in a body fluid sample; and a method of diagnosing cerebral infarction comprising the steps of measuring the nicked β2 glycoprotein I concentration (N) and the total β2 glycoprotein I concentration (T) in a body fluid sample, calculating the ratio (N/T) of the nicked β2 glycoprotein I concentration (N) to the total β2 glycoprotein I concentration (T), and using the ratio as an indicator, are disclosed. | 01-01-2009 |
20090023220 | Method for discriminating between prostatic cancer and benign prostatic hyperplasia - The present invention provides a method for accurately discriminating between prostate carcinoma and benign prostatic hyperplasia based on a glycan structure of prostate specific antigen (PSA). The method of the present invention includes the steps of: purifying PSA from a sample derived from a subject; preparing a PSA derivative from the PSA; labeling the PSA derivative; and analyzing the labeled PSA derivative by the mass spectrometry method, in which the subject is identified as having prostate carcinoma when the ratio of the signal intensity of fucose-unbound glycan to the signal intensity of fucose-bound glycan in the labeled PSA derivative is greater than 1.0, and identified as having benign prostatic hyperplasia when the ratio is 1.0 or less. | 01-22-2009 |
20090104708 | HUMAN LAMININ RECEPTOR CRYSTAL AND USES THEREOF - A human laminin receptor crystal is disclosed. Methods are disclosed for using various computer and non-computer means in order to develop models for use in the development of novel therapeutics that block and/or mimic laminin receptor interactions in the setting of, among others, Alzheimer's disease, other neurological disorders, cancer, and viral and bacterial infections. | 04-23-2009 |
20090142850 | Disintegratable Films for Diagnostic Devices - The invention provides disintegratable film compositions for diagnostic test devices. The films are prepared with a combination of components that yield films of sufficient film strength and desired disintegration profiles. A disintegratable film according to the present invention contains a water soluble high molecular weight component, a water soluble low molecular weight component, and one or more reagents for use in a diagnostic device. Optionally, the films further contain a starch component, a glucose component, a plasticizer and/or a humectant, and/or a filler. The invention further provides a diagnostic testing device, which includes a film according to an embodiment of the invention, and methods of using such devices. | 06-04-2009 |
20100029007 | Biomarker in Inflammatory Diseases - The use of CD1B, or CD1D, respectively as a target for a disorder selected from Systemic Lupus Erythematosus (SLE), Lupus Anticoagulant (LA) Rheumatoid Arthritis (RA) and Idiopathic Thrombocytopenic Purpura; and the use of CD1D as a target in a disorder which is Multiple Sclerosis (MS), e.g. as a biomarker; a method for preparing a diagnostic kit and a method for identifying agents that modulates a disorder which is mediated by elevated levels of CD1B, or CD1D, respectively, in case of CD1B, or CD1D, respectively selected from Systemic Lupus Erythematosus (SLE), Lupus Anticqagulant (LA) Rheumatoid Arthritis (RA) and Idiopathic Thrombocytopenic Purpura; and in case of CD1D a disorder which is Multiple Sclerosis (MS). | 02-04-2010 |
20100129919 | METHODS AND BIOMARKERS FOR DIAGNOSING AND MONITORING PSYCHOTIC DISORDERS - A method of diagnosing or monitoring a psychotic disorder, or predisposition thereto, comprises measuring, in a sample taken from a subject, the level of a biomarker selected from clusterin precursor, inter α-trypsin inhibitor, IgM, apolipoprotein A2 and α2 H5 glycoprotein. | 05-27-2010 |
20100197032 | NANOASSEMBLED COMPLEXES OF NUCLEIC ACIDS, AVIDIN AND POLYMERS, USE AND PREPARATION THEREOF - The present invention discloses new nanoassembled complexes consisting of a central nucleus formed by a high-affinity interaction from nucleic acids and avidin, wherein said nucleus is stabilized in aqueous solutions, even saline, and protected from further unspecific unwanted interactions by means of suitable polymeric agents capable to mask totally or partially the nucleus itself. The nanocomplexes obtained have been shown to be stable in aqueous solutions and to have nanoparticle features. In addition, the nano-complexes have shown characteristics useful for use in biotechnological field and in nanomedicine. | 08-05-2010 |
20100197033 | URINE AND SERUM BIOMARKERS ASSOCIATED WITH DIABETIC NEPHROPATHY - Use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof. | 08-05-2010 |
20100221840 | METHODS FOR TESTING FOR AND INHIBITING THE DEVELOPMENT OF HUNTINGTON'S DISEASE - This invention relates to Huntington's disease and more specifically to methods for testing and inhibiting the development of Huntington's disease. | 09-02-2010 |
20110053280 | Detection of Post-Translationally Modified Peptides with Liquid Crystals - A method for differentiating between a post-translationally modified peptide and a peptide contained in a sample, comprising: (a) contacting the sample with a peptide attachment surface to create a peptidized surface, wherein the sample includes at least one functional group; (b) contacting the peptidized surface with a recognition reagent that selectively binds or forms a complex with the post-translationally modified peptide in the sample to provide an incubated surface; and (c) contacting a liquid crystal with the incubated surface and detecting presence of post-translationally modified peptide in the sample with the liquid crystal. | 03-03-2011 |
20110117659 | QUINAZOLINE-CONTAINING KITS FOR LABELING ALDEHYDE OR KETONE MOIETIES - Novel fluorescent derivitization reagents are described that are suitable for coupling to biomolecules that contain aldehyde or ketone functional groups. In one embodiment is provided reagents that have the following formula: | 05-19-2011 |
20120142116 | MUTANT RAS POLYPEPTIDE CRYSTAL - An object of the present invention is to provide a co-crystal of a Ras polypeptide which adopts a conformation having a pocket on the molecular surface of Ras and GTP or a GTP analog, a production method for the crystal, and a screening method for a Ras function inhibitor based on information about the conformation obtained by X-ray crystallographic analysis using the crystal. The object is achieved by focusing on a mutation which adopts a conformation having a pocket on the molecular surface of Ras, acquiring a mutant Ras polypeptide having introduced therein such mutation, producing a co-crystal of the mutant Ras polypeptide and a GTP analog, and further subjecting the co-crystal to X-ray crystallographic analysis to acquire structural information about the conformation including information about the structure surrounding the pocket. | 06-07-2012 |
20130011925 | Separation Devices and Method For Separating Phosphorylated Peptides and Proteins - Embodiments of the present invention are directed to articles of manufacture, devices, methods and apparatus for performing liquid chromatography featuring a chromatographic sorbent having one or more pentafluorophenyl groups, wherein said one or more pentafluorophenyl groups are a bonded phase on a sorbent selected from the group comprising silica, organic polymers or hybrid organic diene material and said pentafluorophenyl groups are in a mono-, bi-, and tridentate forms. | 01-10-2013 |
20130183762 | METHOD FOR DETECTING ADRENOCORTICOTROPIC HORMONE AND ADSORBENT - A method for detecting adrenocorticotropic hormone comprising: bringing a liquid sample containing adrenocorticotropic hormone into contact with gelled casein to adsorb adrenocorticotropic hormone to the gelled casein; and detecting the adrenocorticotropic hormone adsorbed to the gelled casein is disclosed. An adsorbent of adrenocorticotropic hormone comprising gelled casein is also disclosed. | 07-18-2013 |
20130316463 | METHOD FOR THE PURIFICATION OF A GLYCAN AND/OR A GLYCOCONJUGATE BY CHROMATOGRAPHY USING A STATIONARY PHASE COMPRISING COTTON - A method of purifying a glycan and/or a glycoconjugate comprising the steps of: (a) providing a stationary phase that comprises cotton; (b) applying a glycan and/or glycoconjugate-containing sample to the stationary phase; (c) washing the stationary phase with a first solvent; and (d) eluting the glycan and/or glycoconjugate from the stationary phase with a second solvent. A kit for purifying a glycan and/or glycoconjugate, the kit comprising: a stationary phase comprising cotton; and instructions for purifying a glycan and/or glycoconjugate according to the disclosed method. | 11-28-2013 |
20140024124 | LABELING AGENT FOR ANALYZING POST-TRANSLATIONAL MODIFICATIONS OF SERINE AND THREONINE - A glycoprotein and/or a glycopeptide which are a test substance is heated in the presence of a pyrazolone derivative, an isoxazolone derivative, a hydantoin derivative, a rhodanine derivative, a maleimide derivative, or the like under a basic condition to cleave and label a post-translational modification group for analysis, thereby enabling analysis of a post-translational modification of a serine residue and/or a threonine residue. | 01-23-2014 |
20140065716 | MULTI-DIMENSIONAL CHROMATOGRAPHIC METHODS FOR SEPARATING N-GLYCANS - A multi-dimensional chromatographic method for the separation of N-glycans. The method comprises providing a glycan preparation that includes at least one negatively charged N-glycan. The glycan preparation is then separated by anion-exchange chromatography and at least one secondary chromatographic technique. | 03-06-2014 |
20140099725 | METHODS FOR THE ANALYSIS OF GLYCOPROTEINS OR GLYCOPEPTIDES BY MASS SPECTROMETRY - A method for the analysis of samples including one or more glycopeptides including the steps of separating one or more glycopeptides using a chromatography system to produce a chromatographic eluent, adding a supercharging reagent to the chromatographic eluent, providing the chromatographic eluent and supercharging reagent to a mass spectrometer, ionizing said chromatographic eluent and supercharging reagent in an ion source to produce glycopeptide ions, performing at least one ion ion reaction on at least some of the glycopeptide ions to produce fragment ions, mass analyzing the fragment ions to produce ion ion reaction mass spectral data, and interpreting the ion ion reaction data mass spectral data to provide structural information relating to the glycopeptide. | 04-10-2014 |
20140356968 | METHODS FOR COMPARING A STRUCTURE OF A FIRST BIOMOLECULE AND A SECOND BIOMOLECULE - The present disclosure provides methods to assess structural similarity of a first biomolecule and a second biomolecule by detecting one or more responses of the first and second biomolecule to thermodynamic stress conditions induced by osmotic and dielectric changes including, detecting a shift in fluorescence emission and/or a change in the intensity of the emission. | 12-04-2014 |
20150099306 | TEST CASSETTE READING DEVICE AND READING METHOD THEREOF - A reading device for reading and analyzing a test cassette having an identification code includes a reading unit, used for reading the identification code marked by the test cassette and carrying out interpretation on a plurality of test lines of the test cassette; an operating unit, used for operating the reading device; a processing unit, used for interpreting a test result with the identification code and the test lines; and a display unit, used for displaying the test result of the test cassette. | 04-09-2015 |
20160252518 | QUATERNARY AMINE CONTAINING ISOBARIC TAG FOR QUANTITATIVE GLYCAN PROFILING | 09-01-2016 |
20180024137 | METHODS FOR COMPARING A STRUCTURE OF A FIRST BIOMOLECULE AND A SECOND BIOMOLECULE | 01-25-2018 |
436088000 | Albumin | 4 |
20090258428 | METHOD FOR ANALYZING LOW MOLECULAR WEIGHT COMPOUND IN SAMPLE CONTAINING WATER-SOLUBLE POLYMER AND LOW MOLECULAR WEIGHT COMPOUND - The invention relates to an analysis method which can conduct analysis on low molecular weight compound in a sample containing water-soluble polymer and low molecular weight compound under isocratic conditions without being affected by proteins or the like and in which water-soluble polymer and low molecular weight compound can be separated efficiently and to a column for such an analysis by high performance liquid chromatography, packed with a packing material comprising a crosslinked organic polymer compound obtained by polymerizing glycerin dimethacrylate at 90 mass % or more as starting material, having the exclusion limit molecular weight measured with pullulan of 30000 or less but 3000 or more and having a mass average particle diameter of 0.1 to 100 μm. | 10-15-2009 |
20100330684 | DIAGNOSTIC DEVICE AND METHOD - Diagnostic devices and methods involve comparison of relative levels of first and second components and/or characteristics of a fluid sample (e.g., saliva), preferably using antibodies arranged to interact with selected components, and colorimetric indicators that are bound or released in proportion to relative concentration or amount of the components or characteristics, as indicative of a health condition such as dehydration state, shock state, stress state, disease state, drug consumption, and drug metabolization. Amylase and IgA may be selected as specific salivary components of interest. | 12-30-2010 |
20160041180 | Method for Evaluating Urine Sample, Analyzer, and Analysis System - A method for obtaining information about proteinuria and/or nephropathy from urine samples is provided for evaluating a urine sample that includes detecting proteins in the urine sample with two types of detection reagents that differ in reactivity to at least one urinary protein; and based on an indicator calculated using the results of the detection with the two types of detection reagents. | 02-11-2016 |
20170234885 | METHODS FOR ASSESSING BIOSPECIMEN INTEGRITY | 08-17-2017 |